We are live on ! Find out more
PCYC

Pharmacyclics
PCYC

Delisted

PCYC was delisted on the 22nd of May, 2015.

251 hedge funds and large institutions have $5.08B invested in Pharmacyclics in 2014 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 97 increasing their positions, 89 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more capital inflows, than outflows

Capital inflows: $936M | Capital outflows: $597M

9% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 89

10% less funds holding

Funds holding: 280 → 251 (-29)

27% less call options, than puts

Call options by funds: $112M | Put options by funds: $154M

33% less funds holding in top 10

Funds holding in top 10: 9 → 6 (-3)

47% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 58

Holders
251
Holders Change
-29
Holders Change %
-10.36%
% of All Funds
7.19%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.17%
New
31
Increased
97
Reduced
89
Closed
58
Calls
$112​M
Puts
$154​M
Net Calls
-⁠$41.6​M
Net Calls Change
+$30.5​M

PCYC Hedge Fund Activity: Q2 2014 in Review

251 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Pharmacyclics (PCYC) for Q2 2014, worth a combined $5.08B — down 4% from $5.29B a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of PCYC and 31 opened new positions — a net loss of 27 holders — while 89 trimmed existing stakes and 97 added.

The largest buyer was Janus Henderson Investors US, adding an estimated $225M. The largest seller was Columbus Circle Investors, cutting an estimated $74.7M.

  • 251 institutional investors held Pharmacyclics (PCYC) as of Q2 2014, down from 280 in Q1 2014.
  • Funds reported $5.08B of Pharmacyclics stock for Q2 2014, down 4% quarter-over-quarter.
  • 31 funds opened new Pharmacyclics positions in Q2 2014 and 58 closed out, a net change of -27 holders.
  • The largest Pharmacyclics buyer in Q2 2014 was Janus Henderson Investors US, an estimated $225M added.
  • The largest Pharmacyclics seller in Q2 2014 was Columbus Circle Investors, an estimated $74.7M sold.

Based on aggregated 13F filings for Q2 2014.